Stocktoria
IMMUCELL CORP /DE/ ICCC
Nasdaq · XNAS · stock · In Vitro & In Vivo Diagnostic Substances · website · IPO 1987-05-01
IMMUCELL CORP /DE/ statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Gross margin | 41.4% | 30.0% | 22.1% | 41.2% | 45.0% |
| Operating margin | 6.0% | -6.2% | -32.9% | -12.4% | 1.3% |
| Net margin | -3.8% | -8.1% | -33.1% | -13.4% | -0.4% |
| FCF margin | 4.4% | -0.4% | -37.6% | -29.7% | -8.6% |
| Return on assets | -2.4% | -4.8% | -13.2% | -5.6% | -0.2% |
| Return on equity | -3.8% | -7.8% | -23.1% | -8.2% | -0.2% |
| Debt / equity | 0.34× | 0.33× | — | 0.34× | 0.02× |
| Current ratio | 4.26 | 3.41 | 2.73 | 4.56 | 6.42 |
| Revenue growth | 4.3% | 51.6% | -5.9% | -3.5% | 25.4% |
Source: SEC EDGAR filings · CIK 0000811641 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.